78-week treatment with tramiprosate 100 mg or tramiprosate 150 mg BID	78-week treatment with placebo	Clinical Dementia Rating – Sum of Boxes (CDR-SB)	16080	16314	Neither the planned G × V interaction (P = 0.573) nor the planned contrast for the primary CDR-SB outcome at Week 78 (100 mg vs. Placebo: P = 0.405; 150 mg vs. Placebo: P = 0.837) revealed a statistically significant treatment effect.
78-week treatment with tramiprosate 150 mg BID	78-week treatment with placebo	hippocampus volume (HV) change	1492	1700	These adjusted models showed a trend toward a treatment effect for ADAS-cog (P = 0.098) and indicated significantly less HV loss for tramiprosate 100 mg (P = 0.035) and 150 mg (P = 0.009) compared to placebo.
78-week treatment with tramiprosate 100 mg or tramiprosate 150 mg BID	78-week treatment with placebo	Clinical Dementia Rating – Sum of Boxes (CDR-SB)	17443	17545	The adjusted model for CDR-SB revealed no significant treatment effect (G × V interaction: P = 0.505).
78-week treatment with tramiprosate 100 mg 	78-week treatment with placebo	adverse effects	18971	19075	owever, the incidence of these AEs in the 100 mg BID group was not statistically different from placebo.
78-week treatment with tramiprosate 100 mg or tramiprosate 150 mg BID	78-week treatment with placebo	Alzheimer Disease Assessment Scale – cognitive subscale (ADAS-cog)	17133	17442	The ADAS-cog adjusted model revealed a statistical trend for treatment effect in favour of the two tramiprosate groups (G × V interaction: P = 0.098) while post-hoc planned contrasts showed lower changes from Baseline relative to placebo in the 100 mg BID group at Week 26 (P = 0.065) and Week 52 (P = 0.090).
78-week treatment with tramiprosate 100 mg 	78-week treatment with placebo	adverse effects	1701	1769	The incidence of adverse events was similar across treatment groups.
78-week treatment with tramiprosate 100 mg or tramiprosate 150 mg BID	78-week treatment with placebo	Clinical Dementia Rating – Sum of Boxes (CDR-SB)	16497	16597	No statistical difference relative to placebo was observed for any of the secondary CDR-SB outcomes.
